Trianni Inc., a Californian biotechnology company, launched its Trianni Mouse, a monoclonal antibody discovery platform optimized for isolation of best-in-class therapeutic candidates.
Monoclonal antibodies are one of the most successful biologic therapeutics on the market. More than 30 have been approved for use in humans and hundreds are currently undergoing testing in clinical trials for a broad range of clinical conditions. Among the options currently available for therapeutic antibody discovery, transgenic mice, such as the Trianni Mouse, are useful in their suitability for meeting pharmaceutical research needs.
The Trianni Mouse is an advanced transgenic platform featuring highly engineered antibody genes, generated using state-of-the-art DNA synthesis and genome modification methodology. It replicates the full antibody-producing capacity – or repertoire – of a human being, and features many enhancements designed to improve its performance as a discovery vehicle. Trianni’s technology represents a significant and highly distinctive advance over existing human antibody transgenic mouse platforms.
The Trianni Mouse platform is now available, with additional variations to follow in the first half of 2014.
Trianni is actively seeking partnerships with interested biotechnology and pharmaceutical companies.
Date: September 26, 2013
Source: Trianni Inc.
Filed Under: Drug Discovery